About Intelectin-2
Intelectin-2 (ITLN2) is a protein
from Homo sapiens identified by UniProt accession
Q8WWU7, 325 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Intelectin-2 |
|---|
| UniProt accession | Q8WWU7 |
|---|
| Gene | ITLN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 325 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (47)
Diseases linked to this target (Open Targets).
- Hypocalcemic vitamin D-resistant rickets · score 0.05
- granulocyte count · score 0.05
- blood protein measurement · score 0.05
- non-small cell lung carcinoma · score 0.04
- polyarticular juvenile idiopathic arthritis, rheumatoid factor positive · score 0.04
- X-linked hypophosphatemia · score 0.04
- hereditary hypophosphatemic rickets with hypercalciuria · score 0.04
- Crohn's disease · score 0.04
- Tall stature - scoliosis - macrodactyly of the great toes · score 0.04
- Eiken syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8WWU7-F1 | alphafold | PREDICTED | 91.73 | — |
Amino-acid sequence (325 residues)
MLSMLRTMTR LCFLLFFSVA TSGCSAAAAS SLEMLSREFE TCAFSFSSLP RSCKEIKERC HSAGDGLYFL RTKNGVVYQT FCDMTSGGGG WTLVASVHEN DMRGKCTVGD RWSSQQGNKA DYPEGDGNWA NYNTFGSAEA ATSDDYKNPG YYDIQAKDLG IWHVPNKSPM QHWRNSALLR YRTNTGFLQR LGHNLFGIYQ KYPVKYRSGK CWNDNGPAIP VVYDFGDAKK TASYYSPYGQ REFVAGFVQF RVFNNERAAN ALCAGIKVTG CNTEHHCIGG GGFFPQGKPR QCGDFSAFDW DGYGTHVKSS CSREITEAAV LLFYR
Explore Intelectin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets